Back HIV/HCV Coinfection

HIV/HCV Coinfection

Coverage of the 2013 International AIDS Society Conference

HIVandHepatitis.com coverage of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), June 30-July 3, in Kuala Lumpur, Malaysia.

Conference highlights include antiretroviral therapy strategies, treatment access, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.

Full listing by topic

HIVandHepatitis.com IAS 2013 conference section

7/6/13

alt

 

EASL 2013: HIV/HCV Coinfected Patients More Likely to Develop Cirrhosis, but Treatment Lowers Risk

Sustained response to hepatitis C treatment leads to slow regression of liver fibrosis in people with HIV/HCV coinfection, but they remain at elevated risk for liver cirrhosis compared to those without HCV, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.

alt

Read more:

CROI 2013: Adding Telaprevir Ups Acute Hepatitis C Cure Rate for HIV+ Men [VIDEO]

Adding telaprevir (Incivek) to pegylated interferon/ribavirin for treating HIV positive men with acute sexually transmitted hepatitis C considerably shortens the duration of therapy and improves the likelihood of a cure, according to study findings presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

EASL 2013: HIV/HCV Coinfected at Risk for Decompensation, May Need Prompt Treatment

HIV positive people with hepatitis C coinfection may experience liver decompensation with advanced fibrosis, even before they progress to cirrhosis, and may therefore benefit from earlier antiviral treatment, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.

alt

Read more:

CROI 2013: French Studies Look at Telaprevir and Boceprevir for People with HIV/HCV Coinfection

Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV coinfected prior non-responders in a pair of French studies presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in this week in Atlanta.alt

Read more:

Atripla Label Adds Drug Interactions with Hepatitis C Protease Inhibitors Boceprevir and Telaprevir

The U.S. Food and Drug Administration (FDA) announced this week that the product label information for Atripla -- the HIV single-tablet regimen containing efavirenz/tenofovir/emtricitabine -- has been updated to include information about drug-drug interactions with the hepatitis C virus protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek or Incivo).

alt

Read more:

Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.

Conference highlights include HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions and complications, treatment as prevention and PrEP, new treatments for hepatitis C, and HIV/HBV and HIV/HCV coinfection.

Full listing by topic

HIVandHepatitis.com CROI 2013 conference section

3/4/13

alt

CROI 2013: Advances in Hepatitis C Treatment 2013 [VIDEO]

The advent of direct-acting antiviral agents targeting hepatitis C virus (HCV) have brought about a new era of treatment, but many questions remain about how these new medications will be used in real-world clinical practice.alt

[Produced in collaboration with IFARA]

In a panel discussion following the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta, Cami Graham from Beth Israel Deaconess Medical Center, Kenneth Sherman from the University of Cincinnati, and Kristen Marks from Weill Cornell Medical Center spoke with Liz Highleyman of HIVandHepatitis.com about implications of new therapies for hepatitis C patients and providers.

Read more:

CROI 2013: Retrovirus Conference Starts Sunday in Atlanta

The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) kicks off Sunday, March 3, at the Georgia World Congress Center in Atlanta. HIVandHepatitis.com will be on site next week to bring you breaking news coverage on HIV and hepatitis C.

Look for reports from the HIVandHepatitis.com team and our content partners at NAM/Aidsmap.com starting Monday. Sign up for our email newsletter to get the latest headlines and follow us on Twitter @HIVandHepatitis.alt

Read more:

CROI 2013: New Treatments for Hepatitis C and HIV/HCV Coinfection

New treatments for hepatitis C were a key focus at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) this month in Atlanta. Researchers described several next-generation direct-acting antiviral agents for both HCV monoinfected and HV/HCV coinfected people, as well as some interferon-free regimens.alt

Read more:

Liver Cancer Increasing among People with HIV/HCV Coinfection

Hepatocellular carcinoma (HCC) is a growing problem among HIV positive people coinfected with hepatitis C virus (HCV) in Spain, and it is often diagnosed at a late stage when it is difficult to treat, researchers reported in the January 1, 2013, issue of Clinical Infectious Diseases.

alt

Read more:

CROI 2013: Sofosbuvir + Ribavirin Works Well for Inner-City Hepatitis C Patients

A simple 24-week, all-oral regimen of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 chronic hepatitis C, many of whom had factors predictive of poor response, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.alt

Read more:

Atazanavir (Reyataz) Label Update Adds Kidney Warning, Drug Interactions

Product label information for the HIV protease inhibitor atazanavir (brand name Reyataz) was recently revised to include new warnings about cholelithiasis or gall bladder stones and interstitial nephritis (a type of kidney inflammation), as well as interactions with several other medications, including the hepatitis C virus protease inhibitor boceprevir (Victrelis).

alt

Read more:

CROI 2013: AbbVie Interferon-free Combos Cure Most Newly Treated Hepatitis C Patients

All-oral regimens containing the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor, and ribavirin led to sustained response for more than 90% of previously untreated patients -- including those with unfavorable IL28B gene patterns -- but only about half of prior non-responders, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

alt

Read more:

Coverage of 11th International Congress on Drug Therapy in HIV Infection

HIVandHepatitis.com coverage of the 11th International Congress on Drug Therapy in HIV Infection (HIV11), November 11-15, 2012, Glasgow, Scotland.

Conference highlights include experimental antiretroviral drugs, ART strategies, manging side effects, HIV-related non-AIDS conditions, treatment as prevention and PrEP, HIV/HCV coinfection, and the search for a cure for HIV.

Full listing by topic

HIVandHepatitis.com HIV11 conference section

11/17/12

alt

Presidio and Boehringer Ingelheim Will Collaborate on Interferon-free Hepatitis C Combo

Presidio Pharmaceuticals and Boehringer Ingelheim will jointly conduct a Phase 2a trial to evaluate an all-oral combination containing its NS4A inhibitor PPI-668 plus faldaprevir and BI 207127, with or without ribavirin, for people with hard-to-treat genotype 1a hepatitis C virus.

alt

Read more:

Coverage of the 2012 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

HIVandHepatitis.com AASLD 2012 conference section

11/13/12

alt

CROI 2013: Adding Telaprevir Increases Acute Hepatitis C Cure Rate for HIV+ Men

Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of therapy and improves the likelihood of a cure for HIV positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

alt

Read more:

AASLD 2012: Final Study Results Show Telaprevir Is Safe and Effective for HIV/HCV Coinfected Patients

HIV/HCV coinfected people treated with telaprevir (Incivek) triple therapy are significantly more likely to achieve sustained virological response, or a cure, than people treated with pegylated interferon/ribavirin alone, according to final results from Study 110 presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.alt

Read more:

CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected

Adding the hepatitis C virus (HCV) protease inhibitors simeprevir or faldaprevir to pegylated interferon plus ribavirin produces higher response rates and the potential for shorter treatment for HIV/HCV coinfected people, according to 2 studies presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.alt

Read more:

Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee

The American Association for the Study of Liver Diseases Liver Meeting is the premier annual U.S. conference on althepatology, covering all aspects of liver disease including viral hepatitis, fatty liver, hepatocellular carcinoma, and liver transplantation. Kicking off the meeting on Saturday, AASLD President Guadalupe Garcia-Tsao offered a media overview of some highlights selected from the more than 2000 abstracts to be presented during the week.

Read more: